Illumina, Inc. $ILMN Stake Lessened by Tema Etfs LLC

Key Points

• Tema Etfs LLC reduced its stake in Illumina, Inc. by 75.3%, selling 10,726 shares and leaving it with a remaining 3,513 shares valued at $279,000.
• Illumina reported a quarterly EPS of $1.19, exceeding estimates by $0.17, despite a revenue decrease of 4.8% year-over-year, bringing total revenue to $1.06 billion.
• Analysts have mixed views on Illumina's stock, with a consensus rating of "Hold" and a target price averaging $123.17, reflecting a range of upgrades and downgrades from various brokerages.

Tema Etfs LLC trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 75.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,513 shares of the life sciences company's stock after selling 10,726 shares during the quarter. Tema Etfs LLC's holdings in Illumina were worth $279,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brown Advisory Inc. boosted its holdings in Illumina by 54,220.9% in the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after purchasing an additional 1,909,118 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Illumina by 2,057.5% in the first quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock worth $73,174,000 after buying an additional 879,533 shares in the last quarter. Vanguard Group Inc. lifted its position in Illumina by 3.5% during the first quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock worth $1,298,928,000 after buying an additional 558,243 shares in the last quarter. Pacer Advisors Inc. raised its stake in Illumina by 2,292.9% during the first quarter. Pacer Advisors Inc. now owns 565,680 shares of the life sciences company's stock worth $44,881,000 after purchasing an additional 542,040 shares during the period. Finally, Spyglass Capital Management LLC purchased a new stake in shares of Illumina during the 4th quarter valued at approximately $71,855,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ILMN. Daiwa Capital Markets lowered Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective on the stock. in a research report on Tuesday, August 12th. Scotiabank downgraded shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price on the stock. in a report on Friday, July 11th. Citigroup downgraded shares of Illumina from a "hold" rating to a "strong sell" rating and reduced their price target for the company from $85.00 to $80.00 in a report on Wednesday, July 9th. Daiwa America lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 12th. Finally, Guggenheim reduced their target price on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Six research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $123.06.

Illumina Stock Performance

ILMN traded down $1.73 during trading on Wednesday, reaching $96.09. 445,093 shares of the company were exchanged, compared to its average volume of 2,290,085. The firm has a 50 day moving average of $99.42 and a 200 day moving average of $88.53. The stock has a market cap of $14.77 billion, a P/E ratio of 12.16, a PEG ratio of 2.25 and a beta of 1.43. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the firm earned $0.36 earnings per share. The company's quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.